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E-mail address: hinck@uthscsa.eduTGF-bs are small secreted signaling proteins that function as vital regulators of cellular growth and
differentiation. They signal through a single pair of receptors, known as TbR-I and TbR-II, and are
among the most recently evolved members of the signaling superfamily to which they belong. This
review provides an overview of the TGF-b, BMP, and activin receptor complexes that have been
determined over the past several years. These structures underscore the shared ancestry of the
TGF-bs with the BMPs and activins, but also provide insight as to how the TGF-bs diverged from
the BMPs and activins to bind and assemble their receptors in a distinct manner. These distinctive
modes of receptor binding engender the TGF-bs with high speciﬁcity for their receptors and allow
them to fulﬁll their essential functions in vivo without interference from the many other proteins
of the superfamily.
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Transforming growth factor beta isoforms, TGF-b1, -b2, and -b3,
are small secreted homodimeric signaling proteins. They are pres-
ent only in vertebrates and are required for the proper develop-
ment of several organs and tissues, including the heart, lungs,
eyes, and palate [1–5]. They also perform functions essential for
the long-term survival of humans and other higher vertebrates,
including regulation of the adaptive immune system [6] and coor-
dination of wound healing [7]. The dysregulation of the TGF-b
pathway leads to a number of human diseases and disorders,
including tissue ﬁbrosis [8] and cancer [9–11], demonstrating the
essential roles the TGF-b isoforms have in vivo.
TGF-bs belong to a diversiﬁed family of signaling proteins,
known as the TGF-b superfamily. The other members of the super-
family include the bone morphogenetic proteins (BMPs) which
regulate embryonic patterning [12], the closely related growth
and differentiation factors (GDFs) which regulate cartilage and
skeletal development [13], the activins (Acts) and inhibins (Inhs)
which regulate the release of pituitary hormones [14,15], and oth-
ers, such as Müllerian inhibiting substance (MIS) that regulate sex
determination during embryonic development. The proteins of the
TGF-b superfamily share the same dimeric structure in which the
central 3–1/2 turn helix of one monomer packs against the concavechemical Societies. Published by Esurface formed by the b-strands of the other monomer (Fig. 1). The
majority of family members are further stabilized by an inter-chain
disulﬁde bond that links the monomers together.
There are homologs of the BMPs in worms and ﬂies [16], the
activins/inihibins in ﬂies, but not in worms [17], and TGF-bs in nei-
ther, indicating that the ﬁrst evolved members of the superfamily
were the BMPs/GDFs and that these diverged ﬁrst into the activins/
inhibins and later into the TGF-bs. This is further supported by
phylogenetic analysis of vertebrate superfamily members that
show they progressively diverge from the many different BMP/
GDFs, with activins/inhibins being close intermediates and the
TGF-bs and other proteins that play essential roles in vertebrate
development, including MIS and Lefty, being the most divergent
(Fig. 2).
TGF-bs transduce their signals by binding and bringing together
two single-pass transmembrane receptor kinases into a kinase-ac-
tive heterotetramer [18,19]. These receptors, known as the TGF-b
type I and type II receptors, or TbR-I and TbR-II, are structurally
similar and include small disulﬁde-rich ectodomains that adopt a
three-ﬁnger toxin fold (120 residues) [20], single-spanning trans-
membrane domains (30 residues), and cytoplasmic serine-
threonine kinase domains (400 residues) (Fig. 3). The assembly
of TbR-I and TbR-II into a heterotetramer triggers a transphospho-
rylation cascade that begins with the TbR-II mediated activation of
the TbR-I kinase [21] and is propagated by the TbR-I kinase to
intracellular effectors, including both the canonical receptor-lsevier B.V. All rights reserved.
Fig. 1. Structures of representative proteins of the TGF-b superfamily. Regular secondary structures are depicted, with lighter and darker colors corresponding to the
secondary structures from the two monomers. Disulﬁde bonds are shown as ball and sticks, with the cysteine sidechain atoms in yellow. Structures of the superfamily
proteins are described as curved left hands, with the palm (central a-helix) of one hand resting in the heel (concave surface of the extended b-strands) of the other (lower
left). PDB ﬁles used to generate the structures shown include 1KLC (TGF-b1) [67], 2TGI (TGF-b2) [65], 3BMP (BMP-2) [69], and 1WAQ (GDF-5) [56,73].
Fig. 2. Phylogeneic tree of TGF-b superfamily proteins in humans. The tree was constructed based on an alignment of the mature C-terminal domains. The multiple sequence
alignment and the phylogenetic tree were calculated using the program COBALT [78].
A.P. Hinck / FEBS Letters 586 (2012) 1860–1870 1861mediated Smad proteins (R-Smads) [22,23] and non-Smads [24–
31]. This manner of signaling, including the requirement for a type
I and type II receptor and the type II receptor-mediated activation
of the type I receptor, is shared by all proteins of the superfamily.
The proteins of the superfamily can nevertheless be divided into
two phylogenetic clades based on the type I receptors they bind
and the Smad proteins they activate – the more recently evolved
members of the superfamily, which includes the TGF-bs, activins,
GDF-8, GDF-9, GDF-11, BMP-3, and nodal, bind and signal through
type I receptors that couple to and activate R-Smads 2, 3 (Table 1).
The more distantly related proteins of the superfamily, which in-
cludes BMP-2, -4, -5, -6, -7, -8, -9, and -10 and GDF-1, -3, -5, -6,
and -7, in contrast, bind and signal through type I receptors that
couple to and activate R-Smads 1, 5, and 8 (Table 1). The two sub-
classes of R-Smads, R-Smads 2, 3 and R-Smads 1, 5, and 8, upon
association with the co-mediator Smad, Smad4, assemble distinct
transcriptional complexes and thus activate distinct subsets ofgenes [22]. The TGF-bs are further distinguished from other mem-
bers of the superfamily with regard to their restrictive manner of
receptor binding – thus with one minor exception discussed in
greater detail below, the only receptors that have been reported
to bind and transduce signals for the TGF-bs are TbR-I and TbR-II.
This stands in contrast to the activins, which promiscuously bind
and signal through at least two different type I receptors (ActR-Ib
and TbR-I) and two different type II receptors (ActR-II and ActR-
IIb), and some BMPs and GDFs, which promiscuously bind and sig-
nal through as many as three type I receptors (BMPR-Ia, BMPR-Ib,
and ActR-I) and three type II receptors (ActR-II, ActR-IIb, and
BMPR-II) (Table 1).
The activation of distinct subsets of effector proteins by the two
clades of the superfamily represents an important evolutionary
adaptation that has allowed the superfamily to diversify. The cou-
pling of proteins of the two clades to speciﬁc subsets of R-Smads
necessitates, however, that the receptors bind both the signaling
Fig. 3. The TGF-b type I and type II receptors, TbR-I and TbR-II. The extracellular domains (ECDs) of TbR-I and TbR-II are small (101 and 136 residues, respectively), heavily
disulﬁde-bonded (ﬁve and six disulﬁdes, respectively), and adopt a three-ﬁnger toxin fold (F1, F2, and F3 designate the three ﬁngers of the receptor three-ﬁnger toxin fold).
The transmembrane domain (TMDs) and cytoplasmic serine-threonine kinase domains (S/TKD) are also shown. The type I receptor includes a  20 amino acid
juxtamembrane glycine-serine rich regulatory domain, known as the GS box (GS, purple). The structurally disordered residues between the structured portion of the
ectodomain or kinase domain and the transmembrane domain are shown by dashed lines (14, 22, 8, and 26 residues for the TbR-I ecto, TbR-I kinase, TbR-II ecto, and TbR-II
kinase domains, respectively). The TbR-I ECD, TbR-II ECD, and TbR-I kinase structures are from PDB entries 2PJY, 1M9Z, and 1IAS, respectively. The structure of the TbR-II
kinase domain has not been reported – that shown corresponds to ActR-IIb (PDB entry 2QLU).
Table 1
Signaling protein-receptor pairings in the TGF-b superfamily.
Signaling protein Type I receptora Type II receptor Smad
TGF-bs TbR-I (Alk5) TbR-II Smad2, 3
Activin ActRI-b (Alk4) TbR-I (Alk5) ActR-II, ActR-IIb Smad2, 3
GDF-8 (Myostatin) ActR-Ib (Alk4), TbR-I (Alk5) ActR-II, ActR-IIb Smad2, 3
Nodal ActR-Ib (Alk4), Alk7 ActR-II, ActR-IIb Smad2, 3
BMPs, GDFs Alk1, Act-RI (Alk2) ActR-II, ActR-IIb BMPR-II Smad1, 5, 8
BMPR-Ia (Alk3)
BMPR-Ib (Alk6)
MIS BMPR-Ia (Alk3)
BMPR-Ib (Alk6) MISR-II Smad1, 5, 8
a Type I receptors of the TGF-b superfamily were initially designated as activin-like kinases, or Alks, but
many have since be named according to the major subfamilies of signaling proteins that they serve.
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pinnings of the receptor-R-Smad binding involving the so-called
L45 loop of the type I kinase [32] and the L3 loop of the Smad
MH2 domain [33] have been understood for more than a decade,
while those between the signaling proteins and receptors have
only become apparent in the past few years. These new ﬁndings
will be discussed in the following section with an emphasis on
the restrictive manner by which the TGF-bs bind and assemble
their receptors into signaling complex and how this differs from
the more distantly related BMPs and GDFs, such as BMP-2, BMP-
4, and BMP-7, which promiscuously bind multiple type I and type
II receptors.
2. TGF-bs and BMPs bind and assemble their receptors in a
distinct manner
The mechanisms by which proteins of the superfamily bind and
assemble their receptors into signaling complexes were initially
probed by afﬁnity labeling. The most elegant studies were thosereported for TGF-b using receptor-deﬁcient mink lung epithelial
cells [34]. These studies showed that TGF-b and TbR-II together
crosslink to TbR-I, but TGF-b alone does not. This pattern was also
reported for activin [35], leading to the proposal that TGF-bs and
activins assemble their receptors in an ordered manner, ﬁrst by
binding their type II receptor and then by recruiting their type I
receptor [36]. The BMPs and GDFs, in contrast, exhibited a much
more heterogenous pattern of crosslinking, with some crosslinking
to their receptors in a stepwise manner, while others crosslinked
their receptors when expressed together, but not when either
receptor was expressed alone [37–43]. These ﬁndings, together
with differences in the promiscuity of receptor binding, hinted that
the TGF-bs/activins and BMPs/GDFs might differ in the manner by
which they bind and assemble their receptors into signaling
complexes.
These differences in receptor binding have been borne out by
the structures of the TGF-b and BMP type I type II receptor ternary
complexes determined over the past several years. The structure of
the BMP ternary complex was ﬁrst inferred based on independent
Fig. 4. TGF-b and BMP receptor complexes. (a) Receptor extracellular domains of the TGF-b superfamily adopt the same three ﬁnger toxin fold, as shown by an overlay of the
BMP and TGF-b type I receptors on the left (lavender and tan, respectively), the BMP and TGF-b type II receptors in the middle (magenta and green, respectively), and the TGF-
b type I and type II receptors on the right (tan and green, respectively). (b, c) TGF-b (left) and BMP (right) type I receptor type II receptor ternary complex structures. TGF-b
type I and type II receptors are shaded tan and green, respectively, and extensively contact one another. BMP type I and type II receptors are shaded purple and magenta
respectively, and do not contact one another.
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BMP type I and type II receptors, BMPR-Ia and ActR-II [44,45]
and was later conﬁrmed when the structures of two closely related
BMP ternary complexes, BMP-2:BMPR-Ia:ActR-II and BMP-
2:BMPR-Ia:ActR-IIb, were determined [46,47]. The structure of
the TGF-b ternary complex was initially inferred based on the
structure of TGF-b3 bound to the TbR-II ectodomain and a hypo-
thetical positioning of TbR-I based on BMPR-Ia [48], but this was
revised after the structures of the TGF-b3:TbR-II:TbR-I and TGF-
b1:TbR-II:TbR-I complexes were determined and it was shown that
TbR-I binds differently than BMPR-Ia [49,50].
The structures of the ternary complexes show that although the
signaling proteins and receptors of the BMP and TGF-b subfamilies
share the same overall fold (Figs. 2 and 4a, respectively), they nev-
ertheless bind their receptors in a distinct manner (Fig. 4b and c).
The BMP type I and type II receptors bind to the ‘‘wrist’’ and‘‘knuckle’’ epitopes, respectively, and do not contact one another,
while the TGF-b type I and type II receptors bind to the underside
of the ‘‘ﬁngers’’ and to the ‘‘ﬁngertips’’, respectively, and have
extensive contact. The direct contact between the type I and type
II receptors in the TGF-b complex, but not the BMP, suggested that
TbR-I is recruited by binding both TGF-b and TbR-II. The impor-
tance of direct receptor–receptor contact for the recruitment of
TbR-I was initially conﬁrmed by binding studies with the puriﬁed
receptor ectodomains [49,51]. These studies showed that the
TbR-II ectodomain potentiates the binding of TbR-I ectodomain
by 500-fold or more, whereas similar experiments performed with
BMPs and the BMP receptor ectodomains yielded much more mod-
est effects (potentiation of binding of one receptor by the other
ranging from 0-fold [47] to 3- to 4-fold) [44]. The importance of
the direct receptor–receptor contact for recruitment of TbR-I
into the TGF-b receptor complex has since been conﬁrmed by
Fig. 5. Alternate modes of type II receptor binding for TGF-bs and BMPs. (a) Alternate positions of the BMP and TGF-b type II receptors. Receptors are positioned onto a
common dimer as in the ActR-II:BMP-7 [44] and TbR-II:TGF-b3 [48] crystal structures and are shaded magenta and green, respectively. The b4–b5 loop of ActR-II and TbR-II is
depicted in cyan and red, respectively; b-strand 2 of TbR-II is depicted in yellow. (b) Overlay of the bound forms of ActR-II and TbR-II. Sidechains of the residues in the b4–b5
loop of TbR-II are shown. Receptors are shaded as in panel a. (c) BMP-like manner of type II receptor binding as shown by the positioning of ActR-II (magneta) on the knuckle
epitope of BMP-7 (cyan) as observed in the structure of the ActR-II:BMP-7 complex. Sidechains of the hydrophobic residues on the concave surface of ActR-II are shown. (d)
BMP-like manner of type II receptor binding, but for TbR-II bound to TGF-b3 instead of Act-RII bound to BMP-7. The b4–b5 loop of TbR-II, depicted in red, is shown to sterically
overlap with the ﬁngers. (e) TGF-b-like manner of type II receptor binding, but for ActR-II bound to BMP-7 instead of TbR-II bound to TGF-b3. (f) TGF-b-like manner of type II
receptor binding as shown by binding of one of the edge b-strands of TbR-II (b-strand 2, depicted in yellow) between the ﬁngertips of TGF-b as observed in the structure of the
TbR-II:TGF-b3 complex.
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structure of the ternary complex [49]. These studies, performed
with both the puriﬁed TbR-I and TbR-II ectodomains and the mem-
brane-bound form of the receptors in stably transfected cell lines,
showed that the substitutions had no effect on the ability of TbR-
II to bind TGF-b, but did impair the ability of the TGF-b:TbR-II com-
plex to bind and recruit TbR-I. Thus, the receptor–receptor contacts
identiﬁed in vitro through crystallography and accompanying
binding studies are both required for TGF-b signaling and underlie
the pronounced stepwise manner by which TGF-bs bind and
assemble their receptors in cells.
3. Structural adaptations that enable distinctive modes of
receptor binding
The TGF-b and BMP ternary complexes differ in the manner by
which both receptor types bind (Figs. 5a, 6a). The differences areespecially pronounced for the type II receptor – BMP type II recep-
tors utilize the concave surface of their b-sheet to complement the
convex surface of the knuckle epitope of the BMP (Fig. 5a and c),
while the TGF-b type II receptor inserts one of its edge b-strands
into the cleft between the TGF-b ﬁngertips (Fig. 5a and f). The
two binding modes are further distinguished by the nature of the
interactions, with hydrophobic interactions predominating in the
BMP complex (Fig. 5c) and a combination of hydrophobic, hydro-
gen-bonding, and electrostatic interactions in the TGF-b complex
(Fig. 5f). Though the differences are less pronounced, the type I
receptors also bind differently – BMP type I receptors bind to the
wrist and have extensive contact with both BMP monomers
(Fig. 6c), while the TGF-b type I receptor moves away from the
wrist toward the ﬁngertips where it contacts TbR-II, the TGF-b
monomer to which TbR-II is bound (so-called ‘‘A’’ monomer), and
to a limited extent, the adjacent monomer (so-called ‘‘B’’ mono-
mer) (Fig. 6f). These two binding modes are also distinguished by
Fig. 6. Alternate modes of type I receptor binding for TGF-bs and BMPs. (a) Alternate positions of the BMP and TGF-b type I receptors. Receptors are positioned onto a
common dimer as in the BMPR-Ia:BMP-2 [45] and TbR-II:TbR-IITGF-b3 [49] crystal structures and are shaded purple and tan, respectively. The pre-helix extension in the b4–
b5 loop of TbR-I is shaded red. (b) Overlay of the bound forms of BMPR-Ia and TbR-I. Receptors are shaded as in panel a. (c) BMP-like manner of type I receptor binding as
shown by the positioning of BMPR-Ia (purple) on the wrist epitope of BMP-2 (A monomer blue; B monomer cyan) as observed in the structure of the BMPR-Ia:BMP-2 complex.
Sidechains of Phe85 and other residues on the concave surface of the receptor that interact with BMP-2 are shown. (d) BMP-like manner of type I receptor binding, but for
TbR-I bound to TGF-b3 instead of BMPR-Ia bound to BMP-2. The pre-helix extension in the b4–b5 loop of TbR-I, depicted in red, includes several residues whose sidechains
sterically overlap with residues in the wrist region of TGF-b3. (e) TGF-b-like manner of type I receptor binding, but for BMPR-Ia bound to BMP-2 instead of TbR-I bound to
TGF-b3. (f) TGF-b-like manner of type I receptor binding as shown by binding of the pre-helix extension of TbR-I (depicted in red) in the cleft between TGF-b3 and TbR-II as
observed in the structure of the TbR-I:TbR-II:TGF-b3 complex.
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through a large interface dominated by hydrophobic interactions
(Fig. 6c) and the TGF-b type I receptor binding through a smaller
interface with a combination of hydrophobic and electrostatic
interactions (Fig. 6f).
The structures of the receptor complexes [44–47,49,50], to-
gether with accompanying functional studies [52,53], show that
the repositioning of the receptors is driven by relatively minor,
but important changes in the loop regions of the receptors. The
repositioning of the type II receptor is driven by an extension of
the loop that connects b-strands 4 and 5 of the receptor three-ﬁn-
ger toxin fold (Fig. 5b). This loop is short and oriented away fromthe concave surface of the b-sheet in the BMP type II receptor
(Fig. 5b, cyan), while in the TGF-b type II receptor it is lengthened
by seven residues and folds back onto the concave surface of the
sheet (Fig. 5b, red). The loop in TbR-II is rigidly held in place by
hydrophobic residues that interdigitate with hydrophobic residues
on the underlying sheet (Fig. 5b and d) [54]. The extended loop in
TbR-II precludes binding in a BMP-like manner since it sterically
overlaps with the ﬁngers when bound on the knuckle (Fig. 5d).
The repositioning of the type I receptor is also driven by an exten-
sion of the loop that connects b-strands 4 and 5. The loop is struc-
turally disordered in the unbound of the BMP type I receptor,
BMPR-Ia [55], but undergoes a disorder-to-order transition to form
1866 A.P. Hinck / FEBS Letters 586 (2012) 1860–1870a short helix upon binding [45–47]. This helix includes an exposed
phenylalanine residue, Phe85, that binds in the hydrophobic pock-
et formed by Trp28 and Trp31 on the wrist region of the BMP di-
mer (Fig. 6e). The b4–b5 loop, in contrast, is structurally ordered
in the unbound form of the TGF-b type I receptor, TbR-I, and in
addition to the central helix, also includes a ﬁve-residue ‘pre-helix’
extension in the N-terminal portion of the loop [53] (Fig. 6e). The
pre-helix extension adopts a tight turn with a characteristic N-ter-
minal cis proline [49,50,53] and precludes binding a BMP-like man-
ner since it is rigid [53] and sterically overlaps with the wrist
region of the BMP ‘‘A’’ monomer (Fig. 6d).
The steric overlap caused by the rigid extensions of b4–b5 loop
leads to entirely new interfaces for TbR-II bound to TGF-b3 and for
TbR-I bound to the TGF-b3:TbR-II complex. These interfaces are
illustrated in Figs. 5f and 6f and as shown the interactions that en-
able binding – for TbR-II a central hydrophobic cluster with two
hydrogen-bonded ion pairs at the periphery, and for TbR-I a com-
bination of hydrophobic and electrostatic interactions orchestrated
by the pre-helix extension as it binds deeply in the cleft between
the TGF-b ‘‘A’’ monomer and the adjacent bound TbR-II – are gen-
erally not possible with the corresponding BMP receptors (Figs. 5e
and 6e). The lack of stabilizing interactions is to be expected since
there is no evolutionary pressure to optimize these interactions in
the BMP system – and in fact negative selection may be at work
since binding of the TGF-bs by BMP receptors would lead to inap-
propriate TGF-b signaling, which would presumably have adverse
effects in vivo.
The repositioning of the receptors appears to be have been
important for increasing the range of speciﬁcity within the super-
family. Thus, little or no sharing of receptors has been observed
among signaling proteins that bind their type I and type II recep-
tors through distinct interfaces, while signiﬁcant sharing of recep-
tors has been observed among proteins of the superfamily that
bind their receptors using the same interface. The former is illus-
trated by the TGF-bs and the distantly related BMPs and GDFs
which bind their type I and type II receptors in a distinctive man-
ner and do not share receptors. The latter is illustrated by the dis-
tantly BMPs and GDFs which bind their type I and type II receptors
in the same overall manner [44,45,47,56] and which are well
known to share their receptors [57]. This is further illustrated by
the structures that have been reported for the activins bound to
their type II receptors, ActR-II and ActR-IIb [58,59]. The activin
A:ActR-II and activin A:ActR-IIb structures show that activins also
bind their type II receptors in the same overall as the BMPs and
GDFs, consistent with the sharing of ActR-II and ActR-IIb not only
among the many different BMPs and GDFs, but also among the
activins.
The segregation of the activities of the TGF-bs and the distantly
related BMPs and GDFs is directly dependent upon the speciﬁcity
with which these classes of proteins bind their type I receptors.
The high speciﬁcity with which TGF-bs bind TbR-I is likely depen-
dent on the evolutionary modiﬁcations that gave rise to the alter-
native mode of type I receptor binding. The evolutionary
modiﬁcations that gave rise to the alternative mode of type II
receptor binding however also likely contributes to the speciﬁcity
as this creates the interface between TbR-I and TbR-II. The TbR-
I:TbR-II interface adds an important additional restraint that must
be satisﬁed to enable type I receptor binding, increasing speciﬁcity
even further. The distinctive manner by which the TGF-bs bind
both their type I and type II receptors is therefore likely responsible
for TGF-b’s high speciﬁcity for binding TbR-I and in turn for segre-
gating the activities of the TGF-bs from the other proteins of the
superfamily, particularly the distantly related BMPs and GDFs,
but also more closely related proteins such activins, GDF-8, and no-
dal. This may be important for allowing the TGF-bs to carry out
their indispensible functions – coordinating wound repair andregulating the adaptive immune system – without interference
from the many other proteins of the superfamily.
Though the functional data and structural data amply demon-
strate that TGF-b is highly speciﬁc for binding and recruiting
TbR-I, other type I receptors may be able to bind and signal in place
of TbR-I. The most extensively studied of these is Alk1, which is ex-
pressed at high levels in many types of endothelial cells and which
has been reported to form a mixed receptor complex with TGF-b,
TbR-II, and TbR-I [60]. This complex is reported to activate Smads
1, 5, and 8, in addition to Smads 2 and 3, and has been proposed
to underlie TGF-bs opposing effects on the migration of endothelial
cells. This ‘lateral signaling’ phenomenon has also been shown to
occur in the context of several different normal and transformed
cell lines with the type I receptors ActR-I and BMPR-Ia [61,62].
The fact that these type I receptors are capable of substituting for
TbR-I and transducing signals in response to TGF-b, albeit with sig-
niﬁcantly reduced efﬁciency, may reﬂect the ability of these type I
receptors to transiently bind into the space between TbR-II and
TGF-b, become phosphorylated by TbR-II, and signal. This pre-
sumes that these receptors retain sufﬁcient afﬁnity to bind even
though they lack the critical pre-helix extension. Though further
experimentation is required, this seems plausible given recent
studies that have shown that substitution of the proline residue
on the N-terminal end of the TbR-I pre-helix extension signiﬁcantly
impairs its recruitment into the TGF-b receptor complex, but does
not entirely prevent it [53]. Thus, while TGF-b has clearly evolved
to recruit and signal through TbR-I, there may nevertheless be cir-
cumstances, such as when levels of receptors such as Alk1 are in-
creased, that enable a small proportion of the complexes formed
to include a non-canonical type I receptor, such as Alk1.
4. Activin as an evolutionary intermediate?
The distinct modes of type I and type II receptor binding for the
TGF-bs raise the question as to how these two binding modes
evolved – did these two binding modes simultaneously evolve dur-
ing a period of rapid diversiﬁcation, or did they evolve in a step-
wise manner through an intermediate with a mixed mode of
receptor binding? Though this question cannot be directly ad-
dressed, it is tempting to speculate that the new modes of binding
arose in a stepwise manner, ﬁrst by evolution of a new mode of
type I receptor binding and later by a new mode of type II receptor
binding. This hypothesis is based on our current understanding of
how activins bind their receptors. The activins both share their
type II receptors with the BMPs and bind their type II receptors
in the same overall manner as the BMPs [58,59], unambiguously
demonstrating that they bind their type II receptors in a BMP-like
manner. The activin type I receptor, ActR-Ib, has not yet been
structurally characterized, yet it shares several characteristics with
TbR-I, which also serves as a type I receptor for activins. The ﬁrst is
that it represents the only other known type I receptor of the
superfamily that includes a ‘pre-helix’ extension within the b4–
b5 loop. The extension is similarly positioned in the N-terminal
portion of the loop and it has a similar sequence, including the pro-
line residues on the N- and C-terminal ends shown to be critical for
recruitment of TbR-I into the TGF-b receptor complex (loop se-
quence is PAGKP in ActR-Ib and PRDRP in TbR-I) [53]. The second
is that a systematic study of surface residues of ActR-Ib potentially
involved in receptor binding showed that the residues that most
strongly perturb recruitment of ActR-Ib into the activin receptor
complex map to the pre-helix extension, not to the region on the
concave surface of the b-sheet known to be important for BMP type
I receptor binding [63]. These ﬁndings demonstrate the importance
of ActR-Ib’s pre-helix extension for binding and tentatively sup-
ports the hypothesis that activins bind their type I receptor in a
TGF-b-like manner. The logical extension of this is that all the
A.P. Hinck / FEBS Letters 586 (2012) 1860–1870 1867proteins of the superfamily that bind and signal through type I
receptors that couple to and activate R-Smads 2, 3 bind their type
I receptors in a TGF-b-like manner – whether this is true or not will
require the determination of structures of proteins such as activins,
GDF-8, and nodal bound to type I receptors, such as ActR-Ib and
TbR-I.
This mixed mode of receptor binding, if demonstrated through
direct structural analysis of the activin A:ActR-II:ActR-Ib or activin
A:ActR-IIb:ActR-Ib complex, would position the type I and type II
receptors such that they have a gap of 8–10 Å between them,
necessitating a mechanism other than receptor–receptor contact
as underlying ordered assembly. There are two alternative mecha-
nisms by which this might occur – both involve potentiation of
type I receptor binding by the type II receptor, but by different
mechanisms. The ﬁrst mechanism suggests that the membrane-
bound form of ActR-II or ActR-IIb induces a conformational change
in activin upon binding, thus potentiating the binding of ActR-Ib
[58]. This mechanism was suggested based on the ‘open’ structures
of activin A that have been reported (see below), but has not been
evaluated experimentally by demonstrating either a type II recep-
tor-dependent conformational change in activin or a type II recep-
tor-dependent potentiation of type I receptor binding. The second
mechanism suggests that the high afﬁnity type II receptors, ActR-II
and ActR-IIb, which bind activins with near nanomolar afﬁnity
[58,59], concentrate activin on the cell surface and potentiate the
binding of the low afﬁnity receptor, ActR-Ib. This mechanism has
previously been shown to be important for the ordered assembly
observed with some BMPs, such as BMP-7, which binds the type
II receptor ActR-II with high afﬁnity and in turn recruits the lower
afﬁnity type I receptor BMPR-Ia [64]. Thus, membrane concentra-
tion and reduction of dimensionality might also be important for
ordered receptor assembly by the activins, though this has also
not been evaluated experimentally.
5. Inﬂuence of distinct modes of receptor binding on the
structure of the signaling proteins
The structures shown in Fig. 1 are representative of a number of
superfamily proteins, including the ﬁrst protein of the superfamily
to be structurally characterized, TGF-b2 [65,66], as well as a num-
ber of others since determined, including TGF-b1 [67], TGF-b3 [68],
BMP-2 [69], BMP-3 [70], BMP-6 [70], BMP-7 [71], BMP-9 [72], and
GDF-5 [56,73]. The presumption that all proteins of the superfam-
ily adopt such ‘closed’ dimers was challenged when the structure
of TGF-b3 bound to TbR-II was reported [48]. TGF-b3 was shown
to adopt a non-canonical ‘open’ dimer, characterized by a rotation
of the monomers away from one another and a structural disorder-
ing of the interfacial a-helix (Fig. 7a). The presumption of a com-
mon ‘closed’ dimer was further challenged when activin A was
crystallized with ActR-IIb [59] and was found to adopt an open
state with many of the same characteristics, including a non-
canonical arrangement of the monomers and a disordered helix
(Fig. 7b). There has been one subsequent report indicating that
TGF-b3 adopts an open state [74] (n.b. this paper reports two
TGF-b3 structures – the primary focus of the paper, the antibody-
bound form is found to be ‘closed’, while the unbound form, men-
tioned only in the text, is found to be ‘open’) and two subsequent
reports indicating the activin A adopts an open state [58,75]. These
structures while revealing similar, though not identical open
forms, were determined by independent investigators under en-
tirely different conditions – for example, the most recent structure
of TGF-b3 was determined at pH 7 in the absence of TbR-II,
whereas the previously reported structure was determined at pH
4 in the presence of TbR-II. This suggests the open forms are not
a consequence of the conditions under which the structures weredetermined. This raises questions as to whether the open forms
are peculiar to the TGF-bs and activins and whether such forms
are functionally relevant.
Though there has been little progress made toward directly
addressing these questions, it is nevertheless tempting to speculate
that the open forms might be restricted to the TGF-bs and other
proteins of the superfamily that bind their type I receptors in the
same overall manner as TbR-I. The hypothesis is based on the
TGF-b ternary complex structures [49,50] – in these structures
TGF-b adopts the closed form, TbR-II is bound to residues from a
single monomer, and TbR-I is bound such that it contacts TbR-II
and the TGF-b A-monomer, but only to a limited extent to the adja-
cent B-monomer. The latter is illustrated in Fig. 7c where it is
shown that there is a large water-ﬁlled cleft between TbR-I and
the B-monomer in the structure of the TGF-b3:TbR-II:TbR-I com-
plex. The limited importance of the B-monomer for TbR-I binding
has been demonstrated by binding studies in which the Kd for
recruitment of TbR-I by either a dimeric binary complex (TGF-b3
dimer bound to two equivalents of TbR-II) or a monomeric binary
complex (TGF-b3 monomer, generated by substituting the cysteine
that forms the inter-chain disulﬁde with serine, bound to one
equivalent of TbR-II) was measured and found to be diminished
only 10-fold [49,76]. Thus, disruption of the closed dimer by a rota-
tion of the monomers away from one another as shown in Fig. 7c
would be expected to diminish binding, but only to a limited ex-
tent. This stands in contrast to the much greater reduction in type
I receptor binding afﬁnity that would be expected by rotation of
the BMP and GDF monomers away from one another. The BMP
type I receptors have extensive contact with both monomers and
thus a much greater reduction in type I receptor binding afﬁnity
is expected as the monomers rotate away from one another. This
may account for the fact that all of the BMPs/GDFs that have been
structurally characterized have been found in the closed form.
Thus, TGF-bs and other proteins of the superfamily whose type I
receptors bind with only limited contact with the ‘‘B’’ monomer
(n.b. this may include the activins, as well as other closely related
proteins such as GDF-8, GDF-9, BMP-3, and nodal) achieve only
marginal increases in type I receptor binding afﬁnity by maintain-
ing a closed dimer – these proteins are therefore much more likely
to be found in the open form. BMPs, GDFs and other proteins
whose type I receptors bind with extensive contact to both mono-
mers in contrast are likely to achieve much greater gains in type I
receptor binding afﬁnity by maintaining a closed dimer – these
proteins are therefore much more likely to be found in the closed
form.
There have been no studies yet reported linking the open and
closed forms to the distinct functions of proteins of the superfamily
– one possibility, especially if the effects of the open forms on
receptor binding are minimal, is that they have no major functional
relevance. There are however other functions that the open states
might have acquired – for example, they might enable recognition
by binding proteins that modulate activity or alternatively they
might alter signaling due to a transient opening of the signaling
protein in the context of the signaling complex.
6. Summary and future prospects
The structural studies reported to date have shown that the
TGF-bs diverged from the BMPs and GDFs, the ancestral ligands
of the superfamily, to bind and assemble their type I and type II
receptors in a distinct manner. This diversiﬁcation, with the type
I and type II receptors directly contacting one another in the
TGF-b receptor complex, but not the BMP, is likely important in
preventing other ligands of the superfamily from interfering with
the vital cellular processes that TGF-bs control [77]. There may,
Fig. 7. Structures of the open forms of TGF-b3 and activin A. (a) Structure of TGF-b3 in the canonical closed form in which the two monomers tightly pack against one another
(left) [68] and the open form in which the two monomers are only tethered together by the inter-chain disulﬁde and the central helix is structurally disordered (dashed lines,
right) [48]. A single molecule of TbR-II bound to the ﬁngertips is shown for reference (opening of the dimer does not disrupt the binding site for TbR-II). Opening of the TGF-b3
dimer occurs due to a 100 rotation around an axis parallel to the long dimension of TGF-b. (b) Structure of activin A in the canonical closed form in which the two monomers
tightly pack against one another (left) [79] and the open form in which the two monomers are only tethered together by the inter-chain disulﬁde and the central helix is
structurally disordered (dashed lines, right) [59]. A single molecule of ActR-IIb bound to the knuckles is shown for reference (opening of the dimer does not disrupt the
binding site for ActR-IIb). Opening of the activin A dimer occurs due to a 110 rotation of the two activin A monomers toward one another. (c) Structure of TbR-I:TbR-II:TGF-b3
complex showing that TbR-I mainly contacts TbR-II (green) and the TGF-b monomer to which TbR-II is bound (A monomer, magenta). TbR-I’s pre-helix extension, identiﬁed
by a dashed black line, is shown to bind deeply in the cleft between TbR-II and the TGF-b3 A monomer. The large water-ﬁlled cleft between TbR-I (tan) and the TGF-b3 B-
monomer (pink) is highlighted by the dashed red line.
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ports that type I receptors, such as Alk1, ActR-I, and BMPR-Ia,
may substitute for one of the molecules of TbR-I in the TGF-b
receptor complex and in turn activate BMP Smads (albeit with sig-
niﬁcantly reduced efﬁciency compared to TGF-b Smads).
The receptors appear to have evolved these newmodes of recep-
tor binding in a stepwise manner, ﬁrst by evolution of a new mode
of type I receptor binding and later by evolution of a new mode of
type II receptor binding. This idea is predicated upon the presump-
tion that activins, evolutionary intermediates in the superfamily,
bind their type II receptors in a BMP-like manner and their type I
receptors, ActR-I and TbR-I, in the same overall manner as TbR-I.
The former is known with certainty based on the activin:activin
type II receptor structures that have been reported [58,59], but
the latter is based only inference (inclusion of a ‘pre-helix exten-
sion’ in ActR-Ib, the evolutionary modiﬁcation shown to enable
the distinctive manner by which TbR-I binds, and mutagenesis data
that shows residues within ActR-Ib’s extension are important for
binding [63]). Thus, it will be essential in the future to determine
the structure of the activin bound to either or both of its type I
receptors, ActR-Ib and TbR-I. The other receptor that must be stud-
ied to better understand how the superfamily evolved is the type I
receptor, Alk7. This receptor also activates Smads 2, 3, but unlike
TbR-I and ActR-Ib, Alk7 lacks a pre-helix extension. This raises the
question of whether it has co-evolved the same overall manner of
binding as TbR-I, but without the pre-helix extension, or possibly
whether it found an alternative manner of binding that is distinct
from that of both the BMP type I receptors and TbR-I.
The structural studies have further shown that the presumption
that all proteins of the TGF-b superfamily adopt ‘closed’ dimers in
which the two monomers are tightly packed against one another
may be too simplistic. This is based on two structures of TGF-b3
[48,74] and three structures of activin A [58,59,75] that have
shown the proteins of the superfamily do not always adopt closed
dimers – instead they can adopt ‘open’ forms in which the mono-
mers are loosely packed and held together only by the inter-chain
disulﬁde bond. These ‘open’ forms are hypothesized to arise as aconsequence of differences in receptor binding – speciﬁcally pro-
teins of the superfamily whose type I receptors bind with extensive
contact with both monomers (BMPs, GDFs) ‘demand’ closed dimers
to maintain type I receptor binding, while proteins of the super-
family whose type I receptor bind with limited contact with the
second monomer (TGF-b, and possibly activin) are much more ‘tol-
erant’ and do not ‘demand’ a closed dimer. This idea accounts for
the fact that none of the BMP/GDF structures (0/6) determined to
date have been found in the open form, whereas several of the
TGF-b/activin structures determined to date (5/9) have. This is an
important area for future studies, both from the perspective of
understanding how the proteins of the superfamily have evolved
to fulﬁll their functions, but also in terms of possible new functions
that the open forms might impart.
In summary, the structural knowledge that has been acquired
over the past decade has shed considerable light on how the pro-
teins and receptors of the superfamily have co-evolved to expand
the range of speciﬁcity and thus function within the superfamily.
In the future, this knowledge will provide an invaluable framework
for identifying biologically-relevant interactions between signaling
proteins and receptors of the superfamily that have not yet been
characterized, or are only partially characterized.
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